#Epclusa

These drugs are approved to treat all six major genotypes of hepatitis C.

This from a real-world analysis of people treated for hep C in the United States.

The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.

The subscription-based model is the first of its kind.

What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.

A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Researchers pooled data from numerous real-world cohorts from various nations.

People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.

The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

The high cost of hepatitis C treatment in the U.S. is about to see a major shift to lower prices of the major leading hepatitis C treatments

The drugs are set to come out in January 2019 with a list price of $24,000 for the most common dose for each.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.